Above all, we make a difference.
Home > Breast Cancer Information > Diagnosing Breast Cancer > Diagnosis References

Diagnosis References

  1. American Cancer Society. Breast biopsy. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/breast-biopsy.html, 2019.
  2. American Cancer Society. Risks of cancer surgery. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/surgery/risks-of-cancer-surgery.html, 2019.
  3. Mayo Clinic. Cancer treatment myths: any truth to these common beliefs? https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer/art-20046762, 2020.
  4. Dana-Farber Cancer Institute. Top myths about breast cancer. https://blog.dana-farber.org/insight/2015/10/ten-myths-about-breast-cancer-infographic/, 2020.
  5. Sung JS and Comstock CE. Chapter 15: Image-guided biopsy of nonpalpable breast lesions, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  6. Brancato B, Crocetti E, Bianchi S, et al. Accuracy of needle biopsy of breast lesions visible on ultrasound: audit of fine needle versus core needle biopsy in 3233 consecutive samplings with ascertained outcomes. Breast. 21(4):449-54, 2012.
  7. Rouse HC, Ussher S, Kavanagh AM, Cawson JN. Examining the sensitivity of ultrasound-guided large core biopsy for invasive breast carcinoma in a population screening programme. J Med Imaging Radiat Oncol. 57(4):435-43, 2013.
  8. Youk JH, Kim EK, Kim MJ, Oh KK. Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2,420 cases with long-term follow-up. AJR Am J Roentgenol. 190(1):202-7, 2008.
  9. Ly A, Ono JC, Hughes KS, Pitman MB, Balassanian R. Fine-needle aspiration biopsy of palpable breast masses: patterns of clinical use and patient experience. J Natl Compr Canc Netw. 14(5):527-36, 2016.
  10. Hoda RS, Brachtel EF. International Academy of Cytology Yokohama system for reporting breast fine-needle aspiration biopsy cytopathology: a review of predictive values and risks of malignancy. Acta Cytol. 63(4):292-301, 2019.
  11. Bleicher RJ. Chapter 4: Management of the palpable breast mass, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  12. Moffat FL. Chapter 28: Clinical and pathologic prognostic and predictive factors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  13. Chung AP, Giuliano AE. Chapter 37: Sentinel lymph node biopsy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast cancer treatment, Version 8.2021. http://www.nccn.org, 2021.
  15. Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 364(5):412-21, 2011.
  16. Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 306(4):385-93, 2011.
  17. Dillon D, Guidi AJ, Schnitt SJ. Chapter 25: Pathology of Invasive Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  18. Joe BN. Clinical features, diagnosis, and staging of newly diagnosed breast cancer. In: UpToDate. Burstein H, Vora SR (eds.). Waltham, MA: UpToDate, 2021.
  19. Bleiweiss IJ. Pathology of breast cancer. In: UpToDate. Chagpar AB, Vora SR (eds.). Waltham, MA: UpToDate, 2021.
  20. National Cancer Institute. Inflammatory breast cancer. http://www.cancer.gov/types/breast/ibc-fact-sheet, 2016.
  21. Taghian A and Merajver SD. Inflammatory breast cancer: Clinical features and treatment. In: UpToDate (Hayes DF, Pierce LJ, Chagpar AB, Vora SR, eds.). Waltham, MA: UpToDate, 2021.
  22. National Cancer Institute. Paget Disease of the Breast. http://www.cancer.gov/types/breast/paget-breast-fact-sheet, 2012.
  23. Hansen NM. Chapter 63: Paget’s Disease, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  24. Sabel MS, Weaver DL. Paget disease of the breast (PDB). In: UpToDate (Chagpar AB, Hayes DF, Pierce LJ, Chen W, eds.). Waltham, MA: UpToDate, 2021.
  25. Terando AM, Agnese DM, Holmes DR. Treatment and prognosis of rare breast cancers. Ann Surg Oncol. 22(10):3225-9, 2015.
  26. Lee H, Jung SY, Ro JY, et al. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol. 65(5):441-6, 2012.
  27. Leyrer CM, Berriochoa CA, Agrawal S, et al. Predictive factors on outcomes in metaplastic breast cancer. Breast Cancer Res Treat. 165(3):499-504, 2017.
  28. Ong CT, Campbell BM, Thomas SM, et al. Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a national oncology database. Ann Surg Oncol. 25(8):2249-2260, 2018.
  29. American Cancer Society. Hormone therapy for breast cancer. https://www.cancer.org/cancer/breast-cancer/treatment/hormone-therapy-for-breast-cancer.html, 2019.
  30. Rakha EA, Pinder SE, Bartlett JM, et al. for the National Coordinating Committee for Breast Pathology. Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol. 68(2):93-9, 2015.
  31. Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 67(4):290-303, 2017.
  32. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 30;351(27):2817-26, 2004.
  33. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 28(11):1829-34, 2010.
  34. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 373(21):2005-14, 2015.
  35. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 379(2):111-121, 2018.
  36. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 105(10):701-10, 2013.
  37. Rakovitch E, Nofech-Mozes S, Hanna W, et al. Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. J Natl Cancer Inst. 109(4):djw256, 2017.
  38. Rakovitch E, Sutradhar R, Nofech-Mozes S, et al. 21-gene assay and breast cancer mortality in ductal carcinoma in situ. J Natl Cancer Inst. 113(5):572-579, 2021.
  39. Rakovitch E, Parpia S, Koch A, et al. DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS. Breast Cancer Res Treat. 188(1):133-139, 2021.
  40. Henry NL, Somerfield MR, Abramson VG, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: update of the ASCO endorsement of the Cancer Care Ontario guideline. J Clin Oncol. 37(22):1965-1977, 2019.
  41. Piccart M, van ‘t Veer LJ, Poncet C, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 22(4):476-488, 2021.
  42. Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 35(24):2838-2847, 2017.
  43. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 34(10):1134-50, 2016.
  44. Sestak I, Cuzick J, Dowsett M, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 33(8):916-22, 2015.
  45. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer. 104(1):120-7, 2011.
  46. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 28(10):1684-91, 2010.
  47. Carey LA, Cheang MCU, Perou CM. Chapter 29: Genomics, Prognosis, and Therapeutic Interventions, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  48. Foukakis T, Bergh J. Prognostic and predictive factors in early, non-metastatic breast cancer. In: UpToDate. Burstein HJ, Vora SR (eds.). Waltham, MA: UpToDate, 2021.
  49. Metzger-Filho O, Sun Z, Viale G, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 31(25):3083-90, 2013.
  50. McGuire A, Lowery AJ, Kell MR, Kerin MJ, Sweeney KJ. Locoregional recurrence following breast cancer surgery in the trastuzumab era: a systematic review by subtype. Ann Surg Oncol. 24(11):3124-3132, 2017.
  51. Partridge AH, Hughes ME, Warner ET, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 34(27):3308-14, 2016.
  52. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 107(6), 2015.
  53. Anders CK, Carey LA. ER/PR negative, HER2-negaitve (triple negative) breast cancer. In: UpToDate. Hayes DF, Burstein HJ, Vora SR (eds.). Waltham, MA: UpToDate, 2021.
  54. Scott LC, Mobley LR, Kuo TM, Il’yasova D. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014. Cancer. 125(19):3412-3417, 2019.
  55. Troester MA, Sun X, Allott EH, et al. Racial differences in PAM50 subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 110(2):176-182, 2018.
  56. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER*Explorer. HR-/HER2- (triple negative) Breast cancer (female only): Recent trends in SEER age-adjusted incidence rates, 2010-2018, observed SEER incidence rate, by race/ethnicity, all ages, all stages. National Cancer Institute. Bethesda, MD. Accessed on August 10, 2021. https://seer.cancer.gov/explorer/, 2021.
  57. Martínez ME, Gomez SL, Tao L, et al. Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. Breast Cancer Res Treat. 166(1):185-193, 2017.
  58. Rey-Vargas L, Sanabria-Salas MC, Fejerman L, Serrano-Gómez SJ. Risk factors for triple-negative breast cancer among Latina women. Cancer Epidemiol Biomarkers Prev. 28(11):1771-1783, 2019.
  59. Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 118(11):2787-95, 2012.
  60. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 33(4):304-11, 2015.
  61. Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 384(5):440-451, 2021.
  62. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER*Explorer. HR+/HER2- (Luminal A) breast cancer (female only): Recent trends in SEER age-adjusted incidence rates, 2010-2018, observed SEER incidence rate, by race/ethnicity, all ages, all stages. National Cancer Institute. Bethesda, MD. Accessed on August 10, 2021. https://seer.cancer.gov/explorer/, 2021.
  63. Chollet-Hinton L, Olshan AF, Nichols HB, et al. Biology and etiology of young-onset breast cancers among premenopausal African American women: results from the AMBER Consortium. Cancer Epidemiol Biomarkers Prev. 26(12):1722-1729, 2017.
  64. Walsh SM, Zabor EC, Stempel M, Morrow M, Gemignani ML. Does race predict survival for women with invasive breast cancer? Cancer. 125(18):3139-3146, 2019.
  65. American Cancer Society. Breast Cancer Facts and Figures 2019-2020. Atlanta, GA: American Cancer Society, 2019.
  66. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 2.2021. http://www.nccn.org, 2021.
  67. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 376(22):2147-2159, 2017.
  68. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER*Explorer. HR-/HER2- (triple negative) breast cancer (female only). SEER 5-year age-adjusted incidence rates, 2014-2018. National Cancer Institute. Bethesda, MD. Accessed on August 11, 2021. https://seer.cancer.gov/explorer/, 2021.
  69. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 103(3):250-63, 2011.
  70. Warner ET, Tamimi RM, Boggs DA, et al. Estrogen receptor positive tumors: do reproductive factors explain differences in incidence between black and white women? Cancer Causes Control. 24(4):731-9, 2013.
  71. Palmer JR, Viscidi E, Troester MA, et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst. 106(10), 2014.
  72. Chen L, Li CI, Tang MT, et al. Reproductive factors and risk of luminal, HER2-overexpressing, and triple-negative breast cancer among multiethnic women. Cancer Epidemiol Biomarkers Prev. 25(9):1297-304, 2016.
  73. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 117(16):3658-69, 2011.
  74. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 103(6):470-7, 2011.
  75. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 137(1):307-14, 2013.
  76. Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL for the Breast Cancer Surveillance Consortium. Risk factors that increase risk of estrogen receptor-positive and -negative breast cancer. J Natl Cancer Inst. 109(5): djw276, 2016.
  77. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat. 137(2):579-87, 2013.
  78. Warner ET, Tamimi RM, Hughes ME, et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 33(20):2254-61, 2015.
  79. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 313(2):165-73, 2015.
  80. American Cancer Society. Cancer Facts and Figures for African Americans 2019-2021. Atlanta, GA: American Cancer Society, 2019.
  81. Cho B, Han Y, Lian M, et al. Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer. JAMA Oncol. 7(7):1016-1023, 2021.
  82. Houssami N, Turner R, Macaskill P, et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol. 32(5):392-401, 2014.
  83. Sardanelli F, Trimboli RM, Houssami N. Solving the preoperative breast MRI conundrum: design and protocol of the MIPA study. Eur Radiol. 30(10):5427-5436, 2020.
  84. Vapiwala N, Hwang WT, Kushner CJ, Schnall MD, Freedman GM, Solin LJ. No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy. Cancer. 123(8):1324-1332, 2017.
  85. Feigelson HS, James TA, Single RM, et al. Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg. 216(5):966-75, 2013.
  86. Arnaout A, Catley C, Booth CM, et al. Use of preoperative magnetic resonance imaging for breast cancer: a Canadian population-based study. JAMA Oncol. 1(9):1238-50, 2015.
  87. Houssami N, Turner RM, Morrow M. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. Breast Cancer Res Treat. 165(2):273-283, 2017.
  88. Wang SY, Long JB, Killelea BK, et al. Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat. 172(2):453-461, 2018.
  89. Fairbairn K, Cervantes A, Rayhrer R, Steen S. Trends in contralateral prophylactic mastectomy. Aesthetic Plast Surg. 44(2):323-329, 2020.
  90. Rafferty EA, Park JM, Philpotts LE, et al. Assessing radiologist performance using combined digital mammography and breast tomosynthesis compared with digital mammography alone: results of a multicenter, multireader trial. Radiology. 266(1):104-13, 2013.
  91. Slanetz PJ, Moy L, Baron P, et al. for the Expert Panel on Breast Imaging. ACR Appropriateness Criteria® monitoring response to neoadjuvant systemic therapy for breast cancer. J Am Coll Radiol. 14(11S):S462-S475, 2017.
  92. Fontaine M, Tourasse C, Pages E, et al. Local tumor staging of breast cancer: digital mammography versus digital mammography plus tomosynthesis. Radiology. 291(3):594-603, 2019.
  93. Riegger C, Koeninger A, Hartung V, et al. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients. Acta Radiol. 53(10):1092-8, 2012.
  94. Huynh PT, Lemeshko SV, Mahoney MC, et al. ACR Appropriateness Criteria: stage I breast carcinoma. J Am Coll Radiol. 13(11S):e53-e57, 2016.
  95. Jacene HA, DiPiro PJ, Bellon J, et al. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res Treat. 181(2):383-390, 2020.
  96. Cristofanelli M, Budd GT, Ellis MJ, Stopeck AS, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351(8):781-91, 2004.
  97. Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 15(4):406-14, 2014.
  98. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 368(13):1199-209, 2013.
  99. Visvanathan K, Fackler MS, Zhang Z, et al. Monitoring of serum DNA Methylation as an early independent marker of response and survival in metastatic breast cancer: TBCRC 005 prospective biomarker study. J Clin Oncol. 35(7):751-758, 2017.
  100. Stover DG, Parsons HA, Ha G, et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 36(6):543-553, 2018.
  101. Cullinane C, Fleming C, O’Leary DP, et al. Association of circulating tumor DNA with disease-free survival in breast cancer: a systematic review and meta-analysis. JAMA Netw Open. 3(11):e2026921, 2020.
  102. Harris L, Fritsche H, Mennel R, et al. for the American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25(33):5287-312, 2007.
  103. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 32(31):3483-9, 2014.
  104. Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol. 36(16):1631-1641, 2018.
  105. Mayer IA. Systemic treatment for metastatic breast cancer: general principles, in Up-to-Date (Burstein HJ, Vora SR, eds.). Up-to-Date, 20121.
  106. Bidard FC, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 110(6):560-567, 2018.
  107. Sparano J, O’Neill A, Alpaugh K, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4(12):1700-1706, 2018.
  108. Trapp E, Janni W, Schindlbeck C, et al. for the SUCCESS Study Group. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst. 111(4):380-387, 2019.
  109. Radovich M, Jiang G, Hancock BA, et al. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncol. 6(9):1410-1415, 2020.
  110. Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 5(10):1473-1478, 2019.
  111. Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 385(25):2336-2347, 2021.
  112. American Cancer Society. Cancer Facts & Figures for African Americans: 2022-2024. Atlanta, GA: American Cancer Society, 2022.
  113. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast cancer treatment, Version 2.2022. http://www.nccn.org, 2022.
  114. Surveillance Research Program, National Cancer Institute. SEER*Explorer. HR-/HER2- Breast cancer (female only) – SEER 5-year age-adjusted incidence rates, 2015-2019, female by race/ethnicity, all Ages, all Stages. Accessed on April 26, 2022. https://seer.cancer.gov/explorer/, 2022.

Updated 07/21/22